Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis
Completed · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Atopic Dermatitis
In brief
This study determines the Maximum Tolerable Dose (MTD) by maximum BSA percentage treated and evaluates safety and efficacy of 1.1% w/w AMTX-100 CF versus placebo (vehicle). The study has two parts: Phase I (Part 1): Approximately Twenty-five (25) subjects with various treatable Body Surface Area (BSA) involvement of Mild to Moderate Atopic Dermatitis will be enrolled in the study and treated with 1.1% w/w AMTX-100 CF. Phase II (Part 2): Approximately sixty (60) subjects with Mild to Moderate Atopic Dermatitis with various treatable BSA involvement of Mild to Moderate Atopic Dermatitis will be randomized to be treated with 1.1% w/w AMTX-100 CF3 concentration or Vehicle (Placebo) in the study.
Key facts
- Study ID
- NCT04313400
- Run by
- Amytrx Therapeutics, Inc.
- People needed
- 91
- Starts
- 2020-03-10
- Expected to finish
- 2024-01-02
- Last updated by the study team
- 2025-05-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Amytrx Investigational site — Cerritos, California, United States
- Amytrx Investigational site — Encino, California, United States
- Amytrx Investigational site — Long Beach, California, United States
- Amytrx Investigational site — North Hollywood, California, United States
- Amytrx Investigational site — San Diego, California, United States
- Amytrx Investigational site — Sherman Oaks, California, United States
- Amytrx Investigational site — Miami, Florida, United States
- Amytrx Investigational site — Miramar, Florida, United States
- Amytrx Investigational site — Troy, Michigan, United States
- Amytrx Investigational site — New York, New York, United States
- Amytrx Investigational site — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.